A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib

被引：0
|
作者：
Jewitt, K.
Pilgrim, H. [1 ]
Ward, S. [1 ]
机构：
[1] Univ Sheffield, ScHARR, Sheffield S10 2TN, S Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
105
引用
收藏
页码：38 / 38
页数：1
相关论文
共 50 条
  • [21] Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
    Carla Rognoni
    Camilla Falivena
    Francesco Costa
    Patrizio Armeni
    PharmacoEconomics, 2023, 41 : 209 - 225
  • [22] PANCREATIC EXOCRINE INSUFFICIENCY IN PATIENTS WHO HAVE UNDERGONE SURGERY DUE TO PANCREATIC CANCER: A CHINESE COST-UTILITY ANALYSIS
    Kim, H.
    Byrnes, J.
    Jiang, K.
    Liao, Z.
    Kim, K.
    Fragkogianni, D.
    Roberts, K.
    VALUE IN HEALTH, 2022, 25 (12) : S121 - S122
  • [23] Cost-effectiveness analysis of dasatinib for the treatment of imatinib resistant or intolerant CML patients in Brazil
    Quissak, C.
    Litalien, G.
    Alves, M. R.
    VALUE IN HEALTH, 2008, 11 (03) : A64 - A64
  • [24] Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    Kantarjian, Hagop
    Giles, Francis
    Wunderle, Lydia
    Bhalla, Kapil
    O'Brien, Susan
    Wassmann, Barbara
    Tanaka, Chiaki
    Manley, Paul
    Rae, Patricia
    Mietlowski, William
    Bochinski, Kathy
    Hochhaus, Andreas
    Griffin, James D.
    Hoelzer, Dieter
    Albitar, Maher
    Dugan, Margaret
    Cortes, Jorge
    Alland, Leila
    Ottmann, Oliver G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24): : 2542 - 2551
  • [25] Cost-utility analysis
    Brown, GC
    Brown, MM
    Sharma, S
    ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) : 625 - 626
  • [26] COST-UTILITY ANALYSIS
    NICHOLLS, A
    BRITISH MEDICAL JOURNAL, 1993, 307 (6913): : 1213 - 1213
  • [27] COMPARATIVE ANALYSIS OF PULMONARY HYPERTENSION IN THE 105 CML PATIENTS TREATED WITH IMATINIB, NILOTINIB AND DASATINIB
    Minami, M.
    Miyamoto, T.
    Akashi, K.
    HAEMATOLOGICA, 2017, 102 : 728 - 728
  • [28] Efficacy of Nilotinib in EARLY Chronic PHASE CML Patients WHO Have Suboptimal Cytogenetic or Molecular Response to Imatinib. A Multicentric Retrospective Study
    Luciano, Luigia
    Seneca, Elisa
    Annunziata, Mario
    Pezzullo, Luca
    Danise, Paolo
    Sessa, Ursula
    Palmieri, Fausto
    Iovine, Mariolina
    Vallone, Roberto
    Pane, Fabrizio
    BLOOD, 2012, 120 (21)
  • [29] EFFICACY OF NILOTINIB IN EARLY CHRONIC PHASE CML PATIENTS WHO HAVE SUBOPTIMAL CYTOGENETIC OR MOLECULAR RESPONSE TO IMATINIB. A MULTICENTRIC RETROSPECTIVE STUDY
    Luciano, L.
    Seneca, E.
    Annunziata, M.
    Pezzullo, L.
    Danise, P.
    Palmieri, F.
    Iovine, M.
    Vallone, R.
    Pane, F.
    HAEMATOLOGICA, 2012, 97 : 540 - 540
  • [30] Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
    Giles, F. J.
    Larson, R. A.
    Kantarjian, H. M.
    le Coutre, P.
    Palandri, F.
    Haque, A.
    Gallagher, N.
    Ottmann, O. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345